Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ANIP OTCMKTS:CYDY NASDAQ:ETNB NASDAQ:VERA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANIPANI Pharmaceuticals$63.93+0.9%$64.00$52.50▼$77.00$1.37B0.57303,297 shs318,815 shsCYDYCytoDyn$0.29-1.1%$0.31$0.10▼$0.49$371.16M1.231.20 million shs887,595 shsETNB89BIO$9.16-3.6%$10.02$4.16▼$11.84$1.39B1.281.22 million shs1.11 million shsVERAVera Therapeutics$20.95+0.8%$22.90$18.53▼$51.61$1.33B1.17859,998 shs1.00 million shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANIPANI Pharmaceuticals+0.92%-5.26%-1.98%-12.36%-2.72%CYDYCytoDyn+0.90%-1.35%+8.37%-9.94%+104.90%ETNB89BIO-3.58%-4.48%-9.31%+4.93%0.00%VERAVera Therapeutics+0.77%-3.94%-11.42%-17.23%-42.74%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationANIPANI Pharmaceuticals3.6554 of 5 stars2.51.00.03.32.63.31.3CYDYCytoDyn0.2067 of 5 stars0.01.00.00.03.50.00.0ETNB89BIO2.0459 of 5 stars3.52.00.00.02.00.80.6VERAVera Therapeutics3.4856 of 5 stars4.61.00.00.03.34.20.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceANIPANI Pharmaceuticals 3.00Buy$78.8823.38% UpsideCYDYCytoDyn 0.00N/AN/AN/AETNB89BIO 3.00Buy$26.43188.52% UpsideVERAVera Therapeutics 3.10Buy$65.00210.26% UpsideCurrent Analyst Ratings BreakdownLatest CYDY, ETNB, VERA, and ANIP Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/29/2025ETNB89BIOWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (D-) ➝ Sell (D-)7/12/2025ETNB89BIOWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (D-) ➝ Sell (D-)7/10/2025ANIPANI PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy ➝ Buy$84.006/27/2025ETNB89BIOWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (D-) ➝ Sell (D-)6/11/2025ETNB89BIOWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (D-) ➝ Sell (D-)6/3/2025VERAVera TherapeuticsScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform6/3/2025VERAVera TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy6/2/2025VERAVera TherapeuticsScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetSector Outperform ➝ Sector Outperform$55.00 ➝ $65.006/2/2025VERAVera TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$75.00 ➝ $85.005/24/2025ETNB89BIOWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (D-) ➝ Sell (D-)5/12/2025ANIPANI PharmaceuticalsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$86.00 ➝ $86.00(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookANIPANI Pharmaceuticals$674.07M2.05$7.67 per share8.34$19.11 per share3.35CYDYCytoDynN/AN/A$0.00 per share88.84($0.08) per shareN/AETNB89BION/AN/AN/AN/A$3.34 per shareN/AVERAVera TherapeuticsN/AN/AN/AN/A$9.08 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateANIPANI Pharmaceuticals-$18.52M-$1.27N/A15.19N/A-3.12%21.35%7.52%8/5/2025 (Estimated)CYDYCytoDyn$3.74M$0.0129.29∞N/AN/AN/A-4.40%8/13/2025 (Estimated)ETNB89BIO-$367.08M-$3.38N/AN/AN/AN/A-81.44%-70.17%8/4/2025 (Estimated)VERAVera Therapeutics-$152.15M-$3.00N/AN/AN/AN/A-40.59%-34.54%8/6/2025 (Estimated)Latest CYDY, ETNB, VERA, and ANIP EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025VERAVera Therapeutics-$0.82N/AN/AN/AN/AN/A8/5/2025Q2 2025ANIPANI Pharmaceuticals$1.49N/AN/AN/A$187.18 millionN/A8/4/2025Q2 2025ETNB89BIO-$0.49N/AN/AN/AN/AN/A7/25/2025Q4 2025CYDYCytoDynN/A-$0.01N/A-$0.01N/AN/A5/9/2025Q1 2025ANIPANI Pharmaceuticals$1.37$1.70+$0.33$0.69$179.75 million$197.12 million5/8/2025Q1 2025VERAVera Therapeutics-$0.75-$0.81-$0.06-$0.81N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthANIPANI PharmaceuticalsN/AN/AN/AN/AN/ACYDYCytoDynN/AN/AN/AN/AN/AETNB89BION/AN/AN/AN/AN/AVERAVera TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioANIPANI Pharmaceuticals1.462.661.98CYDYCytoDynN/A0.250.30ETNB89BIO0.0618.0318.03VERAVera Therapeutics0.1027.6827.68Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipANIPANI Pharmaceuticals76.05%CYDYCytoDyn5.06%ETNB89BION/AVERAVera Therapeutics99.21%Insider OwnershipCompanyInsider OwnershipANIPANI Pharmaceuticals11.10%CYDYCytoDyn0.54%ETNB89BIO2.60%VERAVera Therapeutics16.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableANIPANI Pharmaceuticals60021.66 million19.26 millionOptionableCYDYCytoDyn201.25 billion1.25 billionNot OptionableETNB89BIO40145.98 million142.19 millionOptionableVERAVera Therapeutics4063.77 million53.38 millionOptionableCYDY, ETNB, VERA, and ANIP HeadlinesRecent News About These CompaniesFederated Hermes Inc. Cuts Stake in Vera Therapeutics, Inc. (NASDAQ:VERA)4 hours ago | marketbeat.comVera Therapeutics, Inc. (NASDAQ:VERA) Short Interest Up 5,059.7% in JulyAugust 2 at 2:27 AM | americanbankingnews.comPolycythemia Vera Market Expands as FDA Fast Tracks New Treatments and Clinical Trials Show Promising Results | DelveInsightAugust 1 at 1:02 PM | theglobeandmail.comRAPT Therapeutics (RAPT) was upgraded to a Hold Rating at J.P. MorganAugust 1 at 2:59 AM | theglobeandmail.comDecheng Capital LLC Cuts Stock Position in Vera Therapeutics, Inc. (NASDAQ:VERA)July 31 at 6:21 AM | marketbeat.comY Intercept Hong Kong Ltd Makes New $293,000 Investment in Vera Therapeutics, Inc. (NASDAQ:VERA)July 31 at 6:21 AM | marketbeat.comBehind The Volatility Of Vera TherapeuticsJuly 27, 2025 | seekingalpha.comVictory Capital Management Inc. Lowers Stock Holdings in Vera Therapeutics, Inc. (NASDAQ:VERA)July 27, 2025 | marketbeat.comGW&K Investment Management LLC Grows Stock Position in Vera Therapeutics, Inc. (NASDAQ:VERA)July 23, 2025 | marketbeat.comVera Therapeutics, Inc. (NASDAQ:VERA) Stake Decreased by Jennison Associates LLCJuly 21, 2025 | marketbeat.comStartup targets orphan kidney disease with former Merck drugJuly 17, 2025 | medcitynews.comMVera Therapeutics, Inc. (NASDAQ:VERA) Receives Consensus Recommendation of "Buy" from BrokeragesJuly 15, 2025 | marketbeat.comVera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)July 10, 2025 | globenewswire.comVera Therapeutics Reports Positive Phase 3 ORIGIN Trial Results for Atacicept in IgA NephropathyJuly 6, 2025 | msn.comVera Therapeutics Inc Class A Sustainability - MorningstarJuly 5, 2025 | morningstar.comMVera Therapeutics director Enright buys shares worth $5.2mJune 27, 2025 | investing.comVor Bio Reinvents Itself as an Autoimmune Biotech With In-Licensed Phase 3 Asset and $175M in FundingJune 27, 2025 | msn.comInsider Buying: Vera Therapeutics, Inc. (NASDAQ:VERA) Director Acquires 40,607 Shares of StockJune 26, 2025 | insidertrades.comPolycythemia Vera Market Set for Strong Growth Across Key Markets, Backed by Emerging Treatments and Epidemiological Trends | DelveInsightJune 24, 2025 | theglobeandmail.comBAFF- and APRIL-targeted Therapies Market Sees Surge in Activity Amid Rising Autoimmune Disease Burden | DelveInsightJune 24, 2025 | finance.yahoo.comJ.P. Morgan Reaffirms Their Buy Rating on Vera Therapeutics (VERA)June 19, 2025 | theglobeandmail.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesD-Wave Rises 12% in 1 Day, Beating Rivals: What Caused the Spike?By Nathan Reiff | July 22, 2025View D-Wave Rises 12% in 1 Day, Beating Rivals: What Caused the Spike?Buffett's $2B+ Bet With Big Long-Term Potential Just Got UpgradedBy Leo Miller | July 10, 2025View Buffett's $2B+ Bet With Big Long-Term Potential Just Got Upgraded3 Retail Stocks to Watch as Back-to-School Spending Ramps UpBy Chris Markoch | July 14, 2025View 3 Retail Stocks to Watch as Back-to-School Spending Ramps UpNewmont's Financial Strength Sets a High Bar for Gold MinersBy Jeffrey Neal Johnson | August 1, 2025View Newmont's Financial Strength Sets a High Bar for Gold MinersTop 5 AI & Autonomy Stocks Trading Under $15 With Big PotentialBy Ryan Hasson | July 28, 2025View Top 5 AI & Autonomy Stocks Trading Under $15 With Big PotentialCYDY, ETNB, VERA, and ANIP Company DescriptionsANI Pharmaceuticals NASDAQ:ANIP$63.93 +0.58 (+0.92%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$63.55 -0.38 (-0.59%) As of 08/1/2025 05:16 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, group purchasing organizations, specialty pharmacies, and hospitals. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.CytoDyn OTCMKTS:CYDY$0.29 0.00 (-1.15%) As of 08/1/2025 03:59 PM EasternCytoDyn Inc., a clinical-stage biotechnology company, engages in the development of treatments for multiple therapeutic indications. The company is involved in the clinical development of leronlimab, a novel humanized monoclonal antibody targeting the C-C chemokine receptor type 5 receptor in the areas of COVID-19, human immunodeficiency virus (HIV), Metabolic dysfunction-associated steatohepatitis (MASH), and solid tumors in oncology, such as metastatic triple-negative breast cancer. Its leronlimab is currently under phase 2 development for the treatment of NASH, HIV- NASH, and solid tumors, as well as under pre-clinical development for the treatment of HIV-PrEP and HIV-Cure. The company was formerly known as RexRay Corporation. CytoDyn Inc. was incorporated in 2002 and is based in Vancouver, Washington.89BIO NASDAQ:ETNB$9.16 -0.34 (-3.58%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$9.16 0.00 (0.00%) As of 08/1/2025 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis; and for the treatment of severe hypertriglyceridemia. The company was incorporated in 2018 and is headquartered in San Francisco, California.Vera Therapeutics NASDAQ:VERA$20.95 +0.16 (+0.77%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$20.94 -0.01 (-0.05%) As of 08/1/2025 06:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial. It is also developing MAU868, a human monoclonal antibody for the treatment of BK viremia infections. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Alphabet Gains Momentum as Sentiment on Wall Street Improves Amazon's Earnings: What Comes Next and How to Play It Apple Stock: Big Earnings, Small Move—Time to Buy? Tesla Teams With Samsung—Will Other Chipmakers Follow? Will Hims & Hers Fall Along With Novo Nordisk? UPS's 7.5% Dividend: A Blue-Chip Stock on a Once-in-a-Decade Sale AbbVie Stock Eyes Breakout as Pipeline and Profits Grow Why Bloom Energy Stock Could Break to New Highs Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
